Get the Stockscreener App
0.1988
11.96%
-0.027
After Hours:
.20
0.0012
+0.60%
Kala Bio Inc stock is traded at $0.1988, with a volume of 3.39M.
It is down -11.96% in the last 24 hours and down -29.00% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$0.2258
Open:
$0.2236
24h Volume:
3.39M
Relative Volume:
0.52
Market Cap:
$181.17M
Revenue:
$420.00K
Net Income/Loss:
$-35.84M
P/E Ratio:
-0.0335
EPS:
-5.9381
Net Cash Flow:
$-32.12M
1W Performance:
+11.81%
1M Performance:
-29.00%
6M Performance:
-85.90%
1Y Performance:
-94.37%
1-Day Range:
$0.19
$0.2236
1-Week Range:
$0.1726
$0.237
52-Week Range:
$0.1455
$20.60
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.1988 | 205.78M | 420.00K | -35.84M | -32.12M | -5.9381 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-29-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-08-25 | Initiated | Mizuho | Outperform |
| Jul-11-25 | Initiated | Ladenburg Thalmann | Buy |
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
KALA BIO: Q4 Earnings Snapshot - kens5.com
Kala Bio rises on plans to leverage AI - MSN
Should I invest in Palisade Bio Inc before earnings2026 Performance Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Earnings Risk: What is KALA BIO Incs market position2026 Levels & Growth Focused Stock Reports - baoquankhu1.vn
Top 3 Health Care Stocks Which Could Blast Off This Quarter - Benzinga
Kala Pharmaceuticals Inc (27F0.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
KALA Bio launches on-premises AI platform for biotech sector By Investing.com - Investing.com India
KALA BIO Inc. (KALA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kala Bio engages advisor to review clinical assets, AI analytics By Investing.com - Investing.com South Africa
KALA SEC FilingsKala Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Kala Bio Delays 2025 Annual Report Filing - The Globe and Mail
KALA BIO, Inc. (KALA) stock price, news, quote and history - Yahoo Finance UK
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Kala Bio engages advisor to review clinical assets, AI analytics - Investing.com
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities - manilatimes.net
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and ... - Caledonian Record
Kala Bio (NASDAQ: KALA) notifies SEC of late 2025 10‑K, cites turnover - Stock Titan
Bionic Intelligence Research Agent Now Commercially Live for Secure, Scalable, Autonomous Solutions in Global Biotech and Pharma Industries: KALA BIO, Inc. (Nasdaq: KALA) - Barchart.com
Bionic Intelligence Research Agent Now Commercially Live - openPR.com
User - The Chronicle-Journal
Kala Bio deploys AI research agent for biotech clients By Investing.com - Investing.com South Africa
Kala Bio Announces Initial Commercial Deployment of Bionic Intelligence Research Agent - marketscreener.com
Exclusive: Penny stock Kala Bio transitions to revenue model with AI platform launch - MSN
Kala Bio deploys AI research agent for biotech clients - Investing.com
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live - The Manila Times
EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform LaunchKala Bio (NASDAQ:K - Benzinga
KALA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
KALA BIO Inc expected to post a loss of $1.44 a shareEarnings Preview - TradingView
KALA BIO, Inc. (NASDAQ:KALA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Trading Action: Will KALA BIO Inc stock benefit from M A2026 Selloffs & Daily Entry Point Trade Alerts - baoquankhu1.vn
KALA BIO, Inc. (NASDAQ:KALA) Short Interest Up 600.0% in March - MarketBeat
If You Invested $1,000 in Kala Pharmaceuticals Inc (KALA) - Stock Titan
$180 Billion AI Healthcare Emerging Sector Highlighted by Red Light Holland’s Researgency.ai Platform for Biotech & Pharmaceutical Industry: KALA BIO, Inc. (Nasdaq: KALA) - Barchart.com
FinancialContent$180 Billion AI Healthcare Emerging Sector Highlighted by Red Light Holland’s Researgency.ai Platform for Biotech & Pharmaceutical Industry: KALA BIO, Inc. (Nasdaq: KALA) - FinancialContent
KALA BIO (KALA) Projected to Post Quarterly Earnings on Thursday - MarketBeat
KALA Engages AI Technology for Advancing Psilocybin Drug Development - GuruFocus
Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate - Investing News Network
Red Light Holland Deploys Kala Bio AI Platform to Advance Psilocybin Drug PEX010 - tipranks.com
Red Light Holland Engages Kala Bio’s Researgency.AI - GlobeNewswire
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate - TMX Newsfile
AI to speed testing of psilocybin drug PEX010 for addiction and depression - Stock Titan
[144] KALA BIO, Inc. SEC Filing - Stock Titan
Stock Trend Capital Highlights Younet AI’s Exclusive Biotech Partnership with KALA BIO - TipRanks
KALA BIO to launch first commercial AI agent in two weeks - Investing.com Nigeria
KALA BIO, Inc. (NASDAQ:KALA) Short Interest Update - MarketBeat
Why Did KALA Stock Surge 25% Today? - Stocktwits
Form 144 KALA BIO For: 12 March By Investing.com - Investing.com Australia
Kala Bio chases 'Palantir for biotech' dream with new AI platform - MSN
Movement Recap: Does Dragonfly Energy Holdings Corp Equity Warrant have consistent dividend growthQuarterly Trade Report & Expert Curated Trade Ideas - baoquankhu1.vn
Morgan Stanley Smith Barney files Form 144 to sell restricted KALA shares (KALA) - Stock Titan
Form 144: Restricted stock sale notice — Kala Pharmaceuticals (NASDAQ: KALA) - Stock Titan
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):